{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:38:17Z","timestamp":1784860697660,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Event-driven primary endpoints are increasingly used in pulmonary arterial hypertension clinical trials, substantially increasing required sample sizes and trial lengths. The U.S. Food and Drug Administration advocates the use of prognostic enrichment of clinical trials by preselecting a patient population with increased likelihood of experiencing the trial\u2019s primary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study compares validated clinical scales of risk (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, the French score, and Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management [REVEAL] 2.0) to identify patients who are likely to experience a clinical worsening event for trial enrichment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline data from three pulmonary arterial hypertension clinical trials (AMBITION [a Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension], SERAPHIN [Study of Macitentan on Morbidity and Mortality in Patients with Symptomatic Pulmonary Arterial Hypertension], and GRIPHON [Selexipag in Pulmonary Arterial Hypertension]) were pooled and standardized. Receiver operating curves were used to measure each algorithm\u2019s performance in predicting clinical worsening within the pooled placebo cohort. Power simulations were conducted to determine sample size and treatment time reductions for multiple enrichment strategies. A cost analysis was performed to illustrate potential financial savings by applying enrichment to GRIPHON.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>All risk algorithms were compared using area under the receiver operating curve and substantially outperformed prediction per New York Heart Association Functional Class. The REVEAL 2.0\u2019s risk grouping provided the greatest time and sample size savings in AMBITION and GRIPHON for all enrichment strategies but lacked appropriate inputs (i.e., N-terminal-proB-type natriuretic peptide) to perform as well in SERAPHIN. Cost analysis applied to GRIPHON demonstrated the greatest financial benefit by enrolling patients with a REVEAL score \u22658.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This preliminary study demonstrates the feasibility of risk algorithms for pulmonary arterial hypertension trial enrichment and a need for further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202002-0357oc","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:10:31Z","timestamp":1600279831000},"page":"726-736","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":28,"title":["Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials"],"prefix":"10.1093","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-712X","authenticated-orcid":false,"given":"Jacqueline V.","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania"},{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Garnett","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manreet K.","family":"Kanwar","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Allegheny Health Network, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman L.","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Benza","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Allegheny Health Network, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"2026030322084989700_bib1","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.jacc.2015.03.540","article-title":"Management of pulmonary arterial hypertension","volume":"65","author":"McLaughlin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026030322084989700_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.healun.2016.01.020","article-title":"Update in treatment options in pulmonary hypertension","volume":"35","author":"Kanwar","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2026030322084989700_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCOUTCOMES.114.001319","article-title":"Building the case for novel clinical trials in pulmonary arterial hypertension","volume":"8","author":"Ryan","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026030322084989700_bib4","doi-asserted-by":"crossref","first-page":"1801908","DOI":"10.1183\/13993003.01908-2018","article-title":"Clinical trial design and new therapies for pulmonary arterial hypertension","volume":"53","author":"Sitbon","year":"2019","journal-title":"Eur Respir J"},{"key":"2026030322084989700_bib5","article-title":"Enrichment strategies for clinical trials to support approval of human drugs and biological products - guidance for industry","author":"U.S. Food and Drug Administration","year":"2019 [ 2019 ]"},{"key":"2026030322084989700_bib6","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030322084989700_bib7","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030322084989700_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"2026030322084989700_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030322084989700_bib10","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030322084989700_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"2026030322084989700_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026030322084989700_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11336-014-9413-1","article-title":"Rationale and applications of survival tree and survival ensemble methods","volume":"80","author":"Zhou","year":"2015","journal-title":"Psychometrika"},{"key":"2026030322084989700_bib14","article-title":"rpart: recursive partitioning and regression trees","author":"Therneau","year":"2019 [ 2019 ]"},{"key":"2026030322084989700_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/sim.4780010204","article-title":"Tables of the number of patients required in clinical trials using the logrank test","volume":"1","author":"Freedman","year":"1982","journal-title":"Stat Med"},{"key":"2026030322084989700_bib16","article-title":"powerSurvEpi: power and sample size calculation for survival analysis of epidemiological studies","author":"Qiu","year":"2018 [ 2019 ]"},{"key":"2026030322084989700_bib17","article-title":"Procedural payment guide: hospital inpatient and outpatient, ASC and physician reimbursement information","author":"Boston Scientific","year":"2019 [ 2019 ]"},{"key":"2026030322084989700_bib18","article-title":"Pharmacoeconomic review report: selexipeg (Uptravi)","year":"2017"},{"key":"2026030322084989700_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"2026030322084989700_bib20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/biostatistics\/kxt010","article-title":"Adaptive enrichment designs for clinical trials","volume":"14","author":"Simon","year":"2013","journal-title":"Biostatistics"},{"key":"2026030322084989700_bib21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1373\/49.6.976","article-title":"Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease","volume":"49","author":"Mueller","year":"2003","journal-title":"Clin Chem"},{"key":"2026030322084989700_bib22","first-page":"A2512","article-title":"Comparison of risk discrimination between the REVEAL 2.0 calculators, the French Pulmonary Registry algorithm and the Bologna method in patients with Pulmonary Arterial Hypertension (PAH) [abstract]","volume-title":"Am J Respir Crit Care Med","author":"Benza","year":"2020"},{"key":"2026030322084989700_bib23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and drug administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026030322084989700_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.mayocpiqo.2018.04.002","article-title":"Offshore pharmaceutical trials: evidence, economics, and ethics","volume":"2","author":"Yang","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2026030322084989700_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the United States","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin Trials"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/203\/6\/726\/67164499\/ajrccm_203_6_726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/203\/6\/726\/67164499\/ajrccm_203_6_726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:10:43Z","timestamp":1772593843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/203\/6\/726\/8491061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,15]]},"published-print":{"date-parts":[[2021,3,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202002-0357oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2020-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}